michigan glp-1 class action in Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research Kind Patches class action alleges

the research concluded that Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association. This research is in addition to another cohort research in 2025 finding an association between semaglutide usage and NAION in people diagnosed with diabetes

Speak to your doctor for advice

Mounjaro is FDA-approved to treat type 2 diabetes alongside diet and exercise

Rajavashisth, T

Zepbound's potent insulin-sensitizing effect can remove this barrier in a way that diet alone can't

There are no known interactions between the active ingredients in our fiber supplement and GLP-1 agonists drugs like Ozempic or Wegovy